tbuckley/cabot-search huggingface dataset:
Renomedullary Antihypertensive Function in Accelerated (Malignant) Hypertension
Authors: E. E. Muirhead, B. Brooks, J. A. Pitcock, P. Stephenson
Journal: Journal of Clinical Investigation (1972)

The antihypertensive function of the renal medulla was tested on accelerated (malignant) hypertension of the rabbit. A procedure for the development of accelerated hypertension of the rabbit of lethal proportions within 3 wk was established. This procedure consisted of the application of a rigid clip with a fixed and unyielding gap to the left renal artery and removal of the right kidney. Three additional manipulations, other than simple nephrectomy, were performed on the right kidney after application of the rigid clip to the left renal artery. These were: (a) a sham operation, (b) removal of the kidney and separation of the renal cortex and its autotransplantation in a fragmented state, and (c) removal of the kidney and separation of the renal medulla and its autotransplantation in a fragmented state. After the sham-operated kidney and autotransplanted renal medulla, the standardized accelerated hypertension did not develop, whereas after autotransplanted renal cortex it did. After a period of protection against accelerated hypertension, removal of either the sham-operated kidney or the renomedullary transplants was followed by a prompt rise in arterial pressure and death of the animal. Thus, the antihypertensive action of renomedullary tissue was similar to that of the whole kidney. The main cell type noted in the protective renomedullary transplants had the microscopic characteristics of the lipid-containing interstitial cells. These cells occurred in clusters, often were near capillaries, and appeared hyperplastic. It is suggested that the renomedullary interstitial cell is the most eligible cell for exertion of the renomedullary antihypertensive action. Since vasoactive lipids are extractable from the renal medulla and its interstitial cells, the hypothesis that interstitial cells secrete antihypertensive substance(s) is attractive.
O014 : A targeted RNAI screen using a high-throughput infectious model system uncovers glypican gpc5 as a host factor for hepatitis b and d virus entry
Authors: E.R. Verrier, C. Bach, L. Heydmann, A. Weiss, M. Renaud, P. Fritsch, F. Habersetzer, G. Abou-Jaoudé, D. Durantel, C. Schuster, L. Brino, C. Sureau, M.B. Zeisel, T.F. Baumert
Journal: Journal of Hepatology (2015)
A Bio-Bibliography of Edward Jenner, 1749-1823
Authors: Le Fanu
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Impact of enoxaparin on thrombus formation, coronary blood flow, and myocardial perfusion after early invasive treatment during acute coronary syndrome: Results from the SYNERGY library
Authors: Ricardo Costa, Gregg W Stone, Robert Clare, Kenneth W Mahaffey, Robert M Califf, Harvey D White, James J Ferguson, Dietrich C Gulba, Jacques J Col, Alexandra Lansky
Journal: Circulation (2006)
A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma
Authors: C. A. Townsley, L. Elit, M. Carey, A. Afinec, L. Tinker, J. Sturgeon, A. M. Oza
Journal: Journal of Clinical Oncology (2005)

5103 Background: Recurrent and metastatic cervical cancer is not curable with conventional therapy, and the median survival is only about 9 months. High objective response rates have been reported with epirubicin and irinotecan/cisplatin regimens in this patient population and preclinical studies in vitro and in vivo have demonstrated synergistic effects when irinotecan is used in combination with cisplatin or other antineoplastic agents. We report the preliminary findings of a phase II study to evaluate this combination in women with metastatic/locally advanced cervical cancer. Methods: This was a multicenter, open-label, single-stage phase II, prospective trial to evaluate the efficacy and safety of the combination of PIE, in women with histologically or cytologically documented squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix that was unresectable, locally advanced or metastatic. Patients had to have measurable disease as defined by RECIST criteria. No prior chemotherapy for metastatic disease was permitted. Patients received epirubicin (50mg/m2), cisplatin (50mg/m2) and CPT-11 (100mg/m2) intravenously, once every 3 weeks and had tumor assessment performed every 2 cycles. Results: Twenty-two patients have been entered to date, with 21 evaluable for response and toxicity (1 is too early to be assessed). Ten patients had previous platinum chemotherapy and 19 patients had prior radiation. The most frequent adverse events experienced were anemia, leucopenia, fatigue, lymphopenia and alopecia. A total of 19 patients experienced a grade 3 or higher adverse event, occurring across 60 cycles (78%). The most common grade 3 or higher adverse events were leucopenia, neutropenia and lymphopenia. To date there have been 2 patients with complete responses (CR), 4 patients with partial responses (PR), 8 patients with stable disease at cycle 2 and 7 patients progressed after their first evaluation. The combined CR/PR response rate is 28.6%. Conclusions: PIE appears to be active in advanced/metastatic cervical cancer, with manageable toxicities. This study continues to accrue patients. No significant financial relationships to disclose.
New and Nonofficial Remedies: Containing Descriptions of the Articles Which Stand Accepted by the Council on Pharmacy and Chemistry of the American Medical Association on January 1, 1953
Authors: Austin E. Smith
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The medical aspects of life assurance.
Authors: R. D. C. Brackenridge
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 16384: Isoproteronol Facilitated Cardiomyocyte Generation From Human Pluripotent Stem Cells
Authors: Kiwon Ban, Sangsung Kim, Jaemin Byun, Young-Sup Yoon
Journal: Circulation (2011)

Background: While various strategies for cardiomyocyte (CM) differentiation from human pluripotent stem cells (hPSCs), which include embryonic stem cells and induced pluripotent stem cells have bee...
High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study
Authors: S Kapur, G Remington, C Jones, A Wilson, J DaSilva, S Houle, R Zipursky
Journal: American Journal of Psychiatry (1996)

The purpose of this study was to determine the dopamine D2 receptor occupancy induced by low-dose haloperidol treatment in a prospective trial.Seven patients with schizophrenia were treated with 2 mg/day of haloperidol for 2 weeks, and D2 receptor occupancy was measured by [11C]raclopride and positron emission tomography.The patients showed high levels of D2 occupancy (53%-74%); five of them showed substantial clinical improvement, and none showed important side effects.The findings demonstrate that low doses of haloperidol induce D2 receptor occupancies that are in the putative therapeutic range. In combination with recent empirical trials, these findings should encourage clinicians to initiate treatment of psychotic episodes with low (2-4 mg haloperidol equivalent) doses of typical neuroleptics, particularly for first-episode patients.
Studies in the Palæopathology of Egypt.
Authors: Ruffer, Marc Armand, Sir, Roy Lee Moodie
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 9196: Assessment of Left Ventricular Mass in Hypertrophic Cardiomyopathy Patients Bb Real-Time 3-Dimensional Echocardiography in Single-Beat Capture Image; Validation with Cardiac Magnetic Resonance Imaging
Authors: Sung-A Chang, Sang-Chol Lee, Eun-Young Kim, Seung-Hee Hahm, Myung-Kyun Sohn, Eun-young Kim, Sung-Ji Park, Jin-Oh Choi, Joo-Yong Hahn, Seung Woo Park, Yeon Hyeon Choe, Jae K Oh
Journal: Circulation (2011)

Background: Left ventricular (LV) mass is an important prognostic factor in hypertrophic cardiomyopathy (HCM). LV mass can be easily accessed by M-mode or 2D echocardiography; however it includes assumption and might be incorrect in LV with asymmetricity. Real time three dimensional echocardiography (RT3DE) has been introduced as an accurate method to assess the LV mass and recently, RT3DE by single beat capture with online analysis program has been introduced. We validated LV mass using new RT3DE technique compared to cardiac magnetic resonance (CMR). Method: Thirty six HCM patients were consecutively enrolled and 3 patients were excluded due to poor RT3DE images. All the patients underwent CMR and RT3DE within the same day. LV mass was derived from the following methods; the ASE formula (M-mode mass), truncated ellipsoid method by 2D echocardiography (2D mass) and RT3DE (RT3DE mass). RT3DE image was acquired using the SC2000 System. The LV mass data were compared with the LV mass analyzed by CMR. Results: Mean frame rate of RT3DE was 13.1±2.3 frame/second. Pearson's interclass coefficient (ICC) showed close correlation of RT3DE mass and CMR mass (r=0.92 and p&lt; 0.0001). However, M-mode mass and 2D mass had smaller ICC when compared with CMR (r=0.50, p=0.01 and r=0.78, p&lt;0.001) Bland-Altman analysis showed reasonable limits of agreement with small positive bias (15.1). Bias was greater in M-mode LV mass and 2D LV mass (-39.1 and 21.2) Conclusions: LV mass measured by single-beat captured RT3DE is a feasible and accurate method in HCM patients. Because LV shape is asymmetrical in many subjects with HCM, LV mass derived from 2D or M-mode is much more inaccurate than symmetrical LVs. Correct assessment of LV mass using single-beat captured RT3DE will be useful in HCM patients in real clinical practice.
Mechanistic evaluation of the combination effect of paclitaxel (Pac) and bevacizumab (Bev) in breast cancer xenografts
Authors: R. H. Alvarez, V. Valero, R. L. Bassett, C. Lu, N. Dallas, G. Kiriakova, J. A. Bankson, T. L. Madden, G. N. Hortobagyi, J. E. Price
Journal: Journal of Clinical Oncology (2009)

11007 Background: Chemosensitization is the ability to augment the effects of standard chemotherapy. One of the possible mechanisms for chemosensitization is improving intratumoral chemotherapy concentrations by increasing total or regional delivery of chemotherapy to the tumor. This mechanism potentially leads to a decreased tumor interstitial fluid pressure (IFP). This study evaluates the interaction between tumor IFP, intra-tumor drug accumulation and blood vessel perfusion. Methods: GILM2 human breast cancer (triple negative phenotype) cells were injected into the mammary fat pad of female nude mice. Mice were randomized to 4 arms: Control, Pac 24 mg/Kg, Bev 10 mg/Kg, and the same dose for the combination Pac + Bev, twice a week for 3 weeks. Tumor IFP was assessed using an ultraminiature catheter-tip technique (Ozerdem 2005). Concentration of Pac in tumor tissue was measured using liquid chromatography mass spectrometry (LC/MS) and blood vessel perfusion was assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Ultrastructural morphology changes were assessed by electron microscopy (EM). Results: Treatment started 35 days after implantation; tumor tissue concentration of Pac was significantly increased when combined with Bev (P = 0.03). In mice treated with the combination of Pac + Bev, IFP values decreased more gradually, with sustained and significant reduction at the end of the treatment (P = 0.0068; mean SEM day 0: 28,44 ± 6,1; mean SEM day 21: 7,41 ± 2,0). The IFP changes in the other 3 experimental arms did not reach statistical significance. The combination of Pac and Bev produced substantial changes to the proportions of endothelial cell/pericytes and increased apoptosis in tumor cells by 75% (detected by immunostaining for cleaved-caspase 3). Conclusions: The combination of Pac and Bev produces significant tumor reduction and increases three-fold the concentration of Pac in the tumor. This intra-tumor augmentation of Pac was correlated with the decrease of tumor IFP, which was independent of the action of Bev alone. Results of DCE-MRI and EM analyses of the treated tumors will also be presented. No significant financial relationships to disclose.
Biologische Untersuchungen über Farbstoffe
Authors: 巌 松尾
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED- SCLC): Final results of a randomised phase III trial
Authors: D. F. Heigener, L. Freitag, C. Eschbach, R. M. Huber, T. Fink, S. Hummler, N. Banik, M. Wolf
Journal: Journal of Clinical Oncology (2008)

7513 Background: This phase III study was conducted to evaluate the efficacy and safety of TP compared to the standard first- line regimen PE. Methods: Chemotherapy-naïve patients with confirmed ED-SCLC and ECOG performance status ≤ 2 were randomised to receive topotecan (1mg/m2 i.v., d1–5)/cisplatin (75 mg/m2 i.v., d5) or etoposide (100mg/m2 i.v., d1–3)/cisplatin (75 mg/m2 i.v., d1) for a maximum of 6 cycles, q 21 d. Primary objective was to show superiority in OS of TP compared to PE using a two sided log-rank test with a 5% type I error and 80% power. If superiority was not shown, a non-inferiority test was pre-specified (non-inferiority threshold was 10 percentage points relative to the median survival time in the standard arm). Secondary endpoints were 1 year survival rate, objective response rate, time to progression and safety. Results: 795 patients were recruited (358 TP, 345 PE, 92 TE) in 84 centres in Germany and Austria. Baseline characteristics were balanced. Median number of cycles was 6, both for TP and PE. A third study arm topotecan (1mg/m2 i.v., d1–5)/etoposide (80–100 mg/m2 i.v., d3–5) was abandoned in April 2004 following a recommendation of an IDSMB due to an increased number of treatment related deaths. Haematologic toxicity: TP vs. PE: G3/4 neutropenia (35.7/ 35.8%), Gr 3/4 thrombocytopenia (18.7/4.8%), Gr 3/4 anaemia (11.6/6.7%), febrile neutropenia (2.0/2.7%), sepsis (1.7/1.2%), toxicity related deaths (5.2/2.7%). Transfusions of red-cell units (420/153). Non-haematological toxicity was comparable. Conclusion: Topotecan/cisplatin (TP) is non inferior to cisplatin/etoposide (PE) in OS and is superior in TTP and ORR. TP may be considered as an alternative 1st line treatment option for patients with ED-SCLC. TP PE p- value Median survival (months) 99% CI-PP analysis 10.3 9.3–11.3 9.4 8.2–10.9 0.40 1- year survival rate 95% CI 39.7% 34.5%–44.9% 36.1% 30.9%–41.4% 0.29 Median TTP (months) 95% CI 6.9 6.4–7.3 5.9 5.5–6.6 0.004 CR 95% CI 9.5% 6.7%–13.1% 6.9% 4.4%–10.2% 0.21 ORR (CR+PR) 95% CI 55.5% 50.3%–60.7% 45.5% 40.2%–50.8% 0.01 Efficacy results (ITT unless indicated) Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration GlaxoSmithKline
Abstract 15282: {beta}-adrenergic Stimulation Increases Wild Type and LQT2 Mutant Kv11.1 Current in Adult Rat Ventricular Myocyte Expression Model
Authors: Sadguna Y Balijepalli, Evi Lim, Sarah P Concannon, Jasmine Y Liu, David J Tester, Michael J Ackerman, Craig T January
Journal: Circulation (2011)

KCNH2 encodes the α-subunits of Kv11.1 K+ channels that mediate rapidly activating delayed rectifier K+ current (IKr ). Mutations in KCNH2 resulting in type 2 long QT syndrome (LQT2) cause variable...
Comparison of Different Bone Marrow–Derived Stem Cell Approaches in Reperfused STEMI
Authors: J. Alberto San Roman, Pedro L. Sánchez, Adolfo Villa, Ricardo Sanz-Ruiz, María Eugenia Fernandez-Santos, Federico Gimeno, Benigno Ramos, Roman Arnold, Ana Serrador, Hipólito Gutiérrez, Francisco Martin-Herrero, María Jesús Rollán, Felipe Fernández-Vázquez, Juan López-Messa, Pablo Ancillo, German Pérez-Ojeda, Francisco Fernández-Avilés
Journal: Journal of the American College of Cardiology (2015)
Inter-Allied Conferences on War Medicine
Authors: Sir Henry Letheby Tidy, J.M. Browne Kutschbach
Journal: BMJ (1945)

subject.The book is of value to the urologist as well as to the general practitioner and would well repay considerable study.While non-gonorrheal urethritis is a rare disease and is frequently mistakenly diagnosed and difficult to treat, it is a condition that responds readily to correct therapy.Harkness' work will make a valuable and satisfying addition to the library of anyone who is occasionally called on to diagnose urethritis of any origin.